ASND vs AZN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: AZN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ASND and AZN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ASND and AZN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Ascendis Pharma A/S trades on Nasdaq under ASND as American Depositary Shares, each representing one ordinary share of a company headquartered in Hellerup, Denmark. The business is built on TransCon, a prodrug technology that attaches a known parent drug to a carrier through a linker that releases the active molecule slowly and predictably, which lets Ascendis convert daily injections into weekly or monthly dosing. Three products are approved and marketed: SKYTROFA (lonapegsomatropin) for pediatric growth hormone deficiency, YORVIPATH (palopegteriparatide) for adult hypoparathyroidism, and YUVIWEL (navepegritide, developed as TransCon CNP), which received accelerated FDA approval with orphan exclusivity in May 2026 for pediatric achondroplasia. Trailing twelve month revenue is roughly ~EUR 866 million (about ~$1.0 billion), up roughly ~135 percent year over year, with gross margin near ~89 percent.

Full ASND guide

AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. It develops and sells prescription medicines across four main areas: oncology (its biggest engine), cardiovascular-renal-metabolism, respiratory and immunology, and rare disease through Alexion, which it acquired in 2021. Flagship products include the cancer drugs Tagrisso, Imfinzi, Calquence, Lynparza (partnered with Merck) and Enhertu (partnered with Daiichi Sankyo), plus the diabetes and heart-failure drug Farxiga and rare-disease therapies like Ultomiris and Soliris. In 2025 the company reported total revenue of about $58.7 billion, up roughly 9%, and it has set a public ambition to grow that to $80 billion by 2030, with about half expected to come from the United States.

Full AZN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ASND drivers: YORVIPATH is carrying the model; YUVIWEL opens a second large launch.
• AZN drivers: Oncology franchise and the $80 billion ambition; Deep late-stage pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. For AZN, the dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time.

Pick ASND if you believe its drivers more; AZN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ASND and AZN guides.

ASND. The trailing earnings multiple is the number most likely to mislead here, because reported net income of roughly ~EUR 496 million on a trailing basis is driven largely by the roughly ~EUR 679 million deferred tax asset recognized in the first quarter of 2026, not by operations. Price to sales near ~17x and forward price to earnings near ~38x are the cleaner framing, and both price in continued rapid growth from a base that has already tripled. Second quarter 2026 results, scheduled for August 13, 2026, are the next data point on whether the YORVIPATH ramp is holding and how YUVIWEL is converting enrollments into revenue.

AZN. Figures are approximate and tied to the asOf date; confirm live numbers before acting. AstraZeneca trades as a growth-oriented large-cap pharma, so its valuation reflects confidence in the pipeline delivering on the $80 billion 2030 goal more than any single current metric. A patent cliff early next decade means today's revenue base is not guaranteed to persist, so how you weigh future launches matters more than trailing multiples.

Headline figures (approximate, August 2026): ASND shows market cap ~$16.8 billion, revenue (ttm) ~EUR 866 million (about ~$1.0 billion), up ~135% year over year, most recent reported quarter (q1 2026) Revenue ~EUR 247 million; YORVIPATH ~EUR 197 million, SKYTROFA ~EUR 44 million, profitability Gross margin ~89%, operating margin ~-1.7%; Q1 non-IFRS net profit ~EUR 18 million; AZN shows revenue (ttm) Around $60 billion; 2025 total revenue was about $58.7 billion, up roughly 9%, with Q1 2026 up about 8% at constant currency, growth drivers Oncology (Tagrisso, Imfinzi, Calquence, Enhertu, Lynparza), rare disease (Ultomiris, Soliris) and metabolic launches; company ambition of $80 billion revenue by 2030, margins/profitability Solidly profitable large-cap pharma; heavy, sustained R&D spending funds the pipeline that the 2030 target depends on, dividend Pays a regular dividend; recent yield roughly 2%, modest for the sector but backed by large, growing cash flows.

ASND and AZN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ASND and AZN exposure against your real portfolio. It is not an investment adviser.